Abstract
Article AbstractLetter to the Editor Sir: We read with great interest the randomized, double-blind, placebo-controlled clinical trial (RCT) entitled "Osmotic-Release Oral System Methylphenidate Augmentation of Antidepressant Monotherapy in Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Trial" (osmotic-release oral system methylphenidate N = 73, placebo N = 72; mean dose of OROS MPH = 36.4 mg/day), which followed our earlier 4-week RCT (OROS MPH N = 30, placebo N = 30; mean dose of OROS MPH = 34.2 mg/day). In their article, Ravindran et al. referenced our study only in the form of an abstract that was presented in a scientific meeting, without providing any detailed comparisons between the 2 studies. We therefore will briefly introduce our study results using a meta-analytic approach to extract findings from the 2 studies in order to achieve better sample power. We also provide meta-analytic findings from 4 RCTs of modafinil augmentation for unipolar and bipolar depression.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
